Brief: Trevena Announces Completion Of Phase 1 Study For Novel S1p Receptor Modulator
09/11/2022 12:51
Nov 9 (Reuters) - Trevena Inc TRVN.O :
* TREVENA ANNOUNCES COMPLETION OF PHASE 1 STUDY FOR TRV045,
NOVEL
S1P RECEPTOR MODULATOR
* TREVENA INC - NONCLINICAL STUDY SHOWED ANTI-INFLAMMATORY
SIGNALING, SUGGESTING A POTENTIAL DISEASE-MODIFYING EFFECT OF
TRV045 IN TREATMENT OF EPILEPSY
* TREVENA INC - PK PROFILE SUPPORTS ANTICIPATED ONCE DAILY
DOSING
FOR TRV045
* TREVENA INC - COMPANY IS ALSO EXPLORING TRV045 AS A
POTENTIAL
TREATMENT FOR EPILEPSY
Source text for Eikon: ID:nGNX6LV1rb
Further company coverage: TRVN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trevena
See all newsTrevena Inc reports results for the quarter ended in June - Earnings Summary
Trevena Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Trevena Q2 EPS USD -0.23
Brief: Trevena Announces $2M Non-Dilutive Financing Tranche And Reduction In Outstanding Liabilities In Connection With Existing Ex-Us Royalty Financing
U.S. STOCKS ON THE MOVE-Allstate, MicroStrategy, AutoZone